glp-1 novo asks FDA to prevent compounders from making knockoffs GLP-1 Drug Fails to Quell

According to an IQVIA article, by mid-2025, GLP-1s made up more than half of all diabetes prescriptions and 23% of all first-line starts (up from 3% in 2021), displacing metformin and other cheaper generics that historically start the diabetes treatment journey

Mounjaro lawsuits allege that some users may experience stomach paralysis after taking the drug because Mounjaro can delay gastric emptying

On the other end of the spectrum, some women experience diarrhea that typically resolves within the first few weeks of treatment

It did not come with the fanfare of a new drug approval

Those with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasias should not use them